Navigation Links
Harsukh Parmar Joins Roche as Head of Translational and Experimental Medicine - Inflammation
Date:10/10/2011

NUTLEY, N.J., Oct. 10, 2011 /PRNewswire/ -- Today, Roche announced that Harsukh Parmar, MD, has joined the company as the new Head of Translational and Experimental Medicine (TM) for the Inflammation Discovery and Translational Area (DTA). In this role, Harsukh will drive the strategy and implementation of early clinical development in Inflammation and be accountable for TM's role in delivering innovative, first-in-class or best-in-class compounds to the Lifecycle Investment Point. He will also collaborate with Discovery and Clinical Development (late stage) to develop strategies based on biomarkers to ensure the selection of high quality compounds suitable for rapid progression through development.

"I am very pleased to have Harsukh join us. He is recognized worldwide as a leader and expert in respiratory, inflammation, immunology and oncology, and possesses the right combination of experience for this pivotal position," said Jacques Banchereau, PhD, Head of the Inflammation and Virology Discovery and Translational Areas (DTAs) and Nutley's Chief Scientific Officer. "As such, he will also provide valuable expertise and advice on target selection and the development of early stage compounds in our Inflammation pipeline." 

This is the latest in a series distinguished new hires for the Pharma Research and Early Development (pRED) organization, especially the Nutley research site, and further reinforces the company's goal of attracting world-class scientific talent to enhance its research efforts.

"Having previously worked for Roche and recognizing the rich heritage of innovation that has come from the pharma business in small molecules and biologics, I was excited to rejoin a company that has been a leader in many of its respective fields and where innovation is valued, respected and supported even when it requires some level of risk taking," said Harsukh. "This remains my philosophy and I believe this is well aligned with the corporate aims of Roche."

Harsukh joins Roche from Astra Zeneca (AZ) in the UK, where he was Early Development Director, Vice President and Global Head of Early Clinical Development in the Respiratory and Inflammation Therapeutic Area since 2007. During his tenure at AZ, he worked on both small and large molecule projects in respiratory, inflammation, cardiovascular, virology and oncology from Phase I-III and was also accountable for clinical target identification and validation, biomarker development, pathogenetic samples and clinical proof of concept. Prior to this, he served as Director, Global Discovery Medicine and Executive Director, Global Experimental Medicine. Earlier in his career, Harsukh worked for Roche as Global Clinical Science Leader and Director in Oncology, Immunology, Virology and Transplantation in Welwyn, England and was at Pfizer for some time, after more than a decade as an academic consultant with Ipsen Biotech and Debiopharm.

Harsukh earned his medical degree at the University of Aberdeen, Scotland and did postgraduate research at Westminster and Charing Cross Hospitals. He's a recognized expert who has chaired or presented at numerous industry and academic conferences, and is an author or co-author on more than 250 publications. A British citizen, Harsukh and his family will relocate to New Jersey.

About Roche

Headquartered in Basel, Switzerland, Roche is a leader in research-focused healthcare with combined strengths in pharmaceuticals and diagnostics. Roche is the world's largest biotech company with truly differentiated medicines in oncology, virology, inflammation, metabolism and CNS. Roche is also the world leader in in-vitro diagnostics, tissue-based cancer diagnostics and a pioneer in diabetes management. Roche's personalized healthcare strategy aims at providing medicines and diagnostic tools that enable tangible improvements in the health, quality of life and survival of patients. In 2010, Roche had over 80,000 employees worldwide and invested over 9 billion Swiss francs ($8.7B US) in R&D. The Group posted sales of 47.5 billion Swiss francs ($45.6B US). Genentech, United States, is a wholly owned member of the Roche Group. Roche has a majority stake in Chugai Pharmaceutical, Japan. For more information: www.roche.com.


'/>"/>
SOURCE Roche
Copyright©2010 PR Newswire.
All rights reserved

Related medicine technology :

1. General Wesley Clark Joins Immtech as Consulting Strategic Advisor
2. Actress and New Mom Keri Russell Joins PKIDs to launch Silence the Sounds of Pertussis Campaign
3. Video: Actress and New Mom Keri Russell Joins PKIDs to Launch Silence the Sounds of Pertussis Campaign
4. Actress and Mother Jennifer Garner Joins American Lung Association to Encourage Americans to Get an Influenza Vaccination
5. MedicAlert Foundation Joins The Alzheimers Association to Offer MedicAlert(R) + Alzheimers Association Safe Return(R) - Live 24-Hour Emergency Response for Wandering and Medical Emergencies
6. Olympic Gold Medalist Kristi Yamaguchi Joins American Lung Association of Michigan to Address Seriously Low Vaccination Rates; Urge Metro-Detroiters to Get Immunized This Season
7. William R. Ringo Joins Hyperion Therapeutics, Inc. Board of Directors as Chairman
8. Dr. Rajeev Venkayya Joins Gates Foundation as Director of Global Health Delivery
9. Dr. Harriet Robinson Joins GeoVax Team as V.P. of R & D to Accelerate AIDS Vaccine Trials Program
10. Dr. Peter Nash, Ph.D. Joins Mach One Corporation as Chief Scientist
11. Judith Quinlan Joins Cytel as Vice President, Adaptive Trials
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/21/2017)... International plc (NASDAQ: ENDP ) today announced ... network, the Company will be ceasing operations and closing ... Alabama . The closure of the facilities is ... 18 months. The Huntsville location ... and these restructuring actions are intended to better match ...
(Date:7/15/2017)... Enterin Inc., a Philadelphia -based biotechnology company ... the completion of a $12.7 million Series A financing round. ... as the participation of existing investors. ... of New Ventures III and our current investors, and view ... of our platform technology to transform the course of PD ...
(Date:7/13/2017)... -- New York City-based market research firm Kalorama Information notes seven ... From new products to new costs, to the threat of ... study, Potential Pipeline Disruptors . Among them ... 1.  Age-Driven Growth - True Impact Moment Arriving   ... the growing population and, to a more extreme extent, the ...
Breaking Medicine Technology:
(Date:7/21/2017)... ... July 21, 2017 , ... ... selected to renovate and improve the Ramsey County Medical Examiners Facility located in ... Hospital, the $2.5 million project is scheduled to start in late 2017/early 2018. ...
(Date:7/21/2017)... ... 21, 2017 , ... The Margarian Law Firm has filed a class ... ale for allegedly containing no ginger. Dr. Pepper produces the “Canada Dry” brand of ... Margaryan alleges Canada Dry Ginger Ale claims on its bottle that it is made ...
(Date:7/21/2017)... ... July 21, 2017 , ... ... Tears® EyeMist®, the signature product of her research center at Bio-Logic Aqua Research® ... largest population and the greatest number of sufferers of blindness. “We think that ...
(Date:7/20/2017)... Aliso Viejo, CA (PRWEB) , ... July 20, 2017 , ... ... effect when placed between two clips in the FCPX timeline. This effect isolates horizontal ... Each transition in this package contains either a rotating or flipping animation and can ...
(Date:7/20/2017)... ... July 20, 2017 , ... For individuals with extended hospital stays or ... used in such facilities are specially designed to accommodate patients with a wide range ... An inventor from Rochester, Ind., has invented the patent-pending PORTABLE ARM REST, a specially ...
Breaking Medicine News(10 mins):